The stock of ANTISENSE THERAPEUTICS LTD ORDINARY SHAR (OTCMKTS:ATHJF) registered an increase of 1500% in short interest. ATHJF’s total short interest was 1,600 shares in December as published by FINRA. Its up 1500% from 100 shares, reported previously. With 300 shares average volume, it will take short sellers 5 days to cover their ATHJF’s short positions.

It closed at $0.035 lastly. It is down 0.00% since December 6, 2017 and is . It has underperformed by 15.62% the S&P500.

Antisense Therapeutics Limited engages in the research and development of antisense pharmaceuticals in Australia. The company has market cap of $8.69 million. The company's product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of insulin like growth factor 1 receptor for prostate cancer treatment. It currently has negative earnings. The Company’s product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as a potential treatment for diseases associated with excessive growth hormone action.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.